Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Roomies Collab Deck 4: GI and ENT > IBD > Flashcards

IBD Flashcards

1
Q

Sulfasalazine (an aminosalicylate) is a combination of _____________ and _______________

A

5- aminosalicylic acid (5-ASA)

Sulfapyridine (acts only as a carrier to the colonic site of action but still causes side effects; associated sulfonamide side effects are avoided in mesalazine and other newer aminosalicylates)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In the newer aminosalicylates, mesalazine (5-aminosalicylic acid), balsalazide sodium (a pro-drug of 5-aminosalicylic acid) and olsalazine sodium (a dimer of 5-aminosalicylic acid which cleaves in the lower bowel), the sulfonamide-related side-effects of sulfasalazine are avoided, but 5-aminosalicylic acid alone can still cause side-effects including ______________ and _____________ syndrome also seen with sulfasalazine.

A

blood disorders

lupus-like

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which drugs are used in the management of IBD? (3)

A
  1. Aminosalicylates (sulfasalazine and mesalazine); Acute attacks and maintenance of remission in UC and Crohn’s
  2. MTX (with folic acid); acute and maintenance of remission in Crohn’s
  3. Monoclonal antibodies, infliximab, adalimumab, and golimumab (used under specialist supervision)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How often is MTX administered?

A

Weekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Patients taking MTX are warned to report immediately the onset of any features of _______________, _______________, and _______________

A

blood disorders (e.g. sore throat, bruising, and mouth ulcers)

liver toxicity (e.g. nausea, vomiting, abdominal discomfort, and dark urine

respiratory effects (e.g. shortness of breath)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Methotrexate should be taken ____________ in autoimmune conditions and, less commonly, in some cancer therapy regimens. A European review highlighted continued reports of inadvertent overdose due to more frequent dosing (including daily administration), which has resulted in some _______________.

A

once a week

Fatalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

True or false: MTX should be taken daily

A

False; may result in fatal overdose if taken more frequently than once a week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the contraindications to using MTX? (4)

A
  1. Active infection
  2. Ascites
  3. Immunodeficiency syndrome
  4. Significant pleural effusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the mechanism of action of MTX?

A

Immunosuppressant that works by inhibiting enzymes responsible for nucleotide synthesis, thereby preventing cell division and leading to anti-inflammatory action (also leads to dangerous side effects such as bone marrow suppression)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MTX should be used with caution in which patients? (7)

A

Patents with:

  1. Psoriasis lesions (ulceration reported)
  2. Dehydration (increased risk of toxicity)
  3. Diarrhea
  4. Blood disorders
  5. Peptic ulceration or ulcerative stomatitis
  6. Risk of pleural effusion or ascites
  7. Ulcerative colitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In patients taking MTX, _______________ can occur abruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim)

A

Bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In patients taking MTX, bone marrow suppression can occur abruptly; factors likely to increase toxicity include _______________, _______________, and ________________

A

advanced age

renal impairment

concomitant use with another anti-folate drug (e.g. trimethoprim)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Manufacturer advises a clinically significant drop in ______________ or ______________ calls for immediate withdrawal of methotrexate and introduction of supportive therapy.

A

white cell count

platelet count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Manufacturer advises a clinically significant drop in white cell count or platelet count calls for ___________________ of methotrexate and introduction of _________________.

A

immediate withdrawal

supportive therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Manufacturer advises withdraw treatment with MTX if _____________ or ____________ develops—may be first sign of gastro-intestinal toxicity

A

stomatitis

diarrhoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Manufacturer advises withdraw treatment of MTX if stomatitis or diarrhoea develops—may be first sign of ________________

A

gastro-intestinal toxicity

17
Q

In addition to causing bone marrow suppression, MTX has been associated with ____________, ____________, and ____________ toxicity

A

GI

Liver

Pulmonary

18
Q

______________ has been reported in patients taking MTX. Manufacturer advises treatment should not be started or should be discontinued if any abnormality of liver function or liver biopsy is present or develops during therapy.

A

Liver cirrhosis

19
Q

Can patients’ liver function return to normal after stopping MTX therapy?

A

Yes, abnormalities can return to normal within 2 weeks after which treatment may be recommenced if judged appropriate

20
Q

Liver function abnormalities can return to normal within 2 weeks of withdrawing MTX after which treatment may be recommenced if judged appropriate. However, ___________________ may necessitate dose reduction or discontinuation.

A

Persistent increases in liver transaminases

21
Q

For patients taking MTX, advise patients to seek medical attention if dyspnea, cough, or fever develop; discontinue if ______________ is suspected

A

Pneumonitis

22
Q

Coprescription of MTX with which drugs requires increased monitoring or avoidance? (4)

A
  1. NSAIDs due to increased risk of MTX toxicity
  2. Live vaccines due to risk of generalized infection (AVOID)
  3. Other immunosuppressants
  4. Penicillins due to increased risk of toxicity
23
Q

What are the common or very common side effects associated with MTX use? (8)

A
  1. Necrotizing demyelination leukoencephalopathy (with intrathecal use)
  2. Neurotoxicity (with intrathecal use)
  3. Anemia, fatigue
  4. Diarrhea, vomiting, decreased appetite
  5. Headache
  6. Increased risk of infection
  7. Respiratory disorders, dyspnea
  8. Skin reactions
24
Q

_______________ decreases mucosal and gastrointestinal side-effects of methotrexate and may prevent hepatotoxicity; there is no evidence of a reduction in haematological side-effects

A

Folic acid

25
Q

Folic acid decreases _______________ side-effects of methotrexate and may prevent ______________; there is no evidence of a reduction in ______________ side-effects

A

mucosal and gastrointestinal

hepatotoxicity

haematological

26
Q

Treatment with _______________ may be required in acute MTX toxicity.

A

folinic acid (as calcium folinate)

27
Q

Manufacturer advises effective contraception during and for at least _____________ after treatment with MTX in men and women.

A

6 months

28
Q

Is MTX safe to use in pregnancy and/or breastfeeding?

A

No teratogenic; fertility may be reduced during therapy but this may be reversible (discontinue 6 months before trying to conceive)

Discontinue if breast-feeding

29
Q

Is MTX safe to use in hepatic and/or renal impairment?

A

When used for malignancy, avoid in severe hepatic impairment—consult local treatment protocol for details.

Avoid with hepatic impairment in non-malignant conditions—dose-related toxicity.

Risk of nephrotoxicity at high doses.

Use with caution and reduce dose; avoid in severe impairment.

30
Q

What pre-treatment screening is necessary before starting MTX? (2)

A
  1. Exclude pregnancy
  2. FBC, renal, and liver function tests

(NOT PFTs)

31
Q

What are the monitoring requirements for patients taking MTX? (2)

A
  1. FBC and renal and LFTs repeated every 1-2 weeks until therapy is stabilized, then monitoring every 2-3 months
  2. Be advised to report all symptoms and signs suggestive of infection, especially sore throat
32
Q

Patients taking MTX should be advised to avoid self-medication with _____________ or _____________.

A

over-the-counter aspirin

ibuprofen

33
Q

What is the dose of folate given to patients to prevent MTX-induced side effects?

A

5mg once weekly; dose to be taken on a different day to MTX

34
Q

Folate should never be given alone for the treatment of _______________ or other ___________________

A

Pernicious anemia

megaloblastic anaemias caused by vitamin B12 deficiency (may precipitate subacute combined degeneration of the spinal cord)

35
Q

What are the side effects of folate? (5)

A
  1. Abdominal distension
  2. Decreased appetite
  3. Flatulence
  4. Nausea
  5. Vit B12 deficiency exacerbated

Roomies Collab Deck 4: GI and ENT (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions